Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database

Advances in Therapy

Volumn 27, Issue 4, 2010, Pages 223-232

  Zhang, Qiaoyi ^a   Rajagopalan, Srini ^b   Mavros, Panagiotis ^a   Engel, Samuel S ^a   Davies, Michael J ^a   Yin, Donald ^a   Radican, Larry ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Med Data Analytics Inc   (United States)

Author keywords

Antihyperglycemic agents; Baseline characteristics; Exenatide; Incretins; Sitagliptin; Type 2 diabetes

Indexed keywords

CREATININE; EXENDIN 4; HEMOGLOBIN A1C; SITAGLIPTIN;

ADULT; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; COMORBIDITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEMOGRAPHY; DRUG EFFICACY; DRUG INDICATION; ELECTRONIC MEDICAL RECORD; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PRESCRIPTION; SEX DIFFERENCE; UNITED STATES;

ADULT; AGE FACTORS; AGED; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; LIPIDS; MALE; MIDDLE AGED; PEPTIDES; PYRAZINES; RETROSPECTIVE STUDIES; SEX FACTORS; SOCIOECONOMIC FACTORS; TRIAZOLES; VENOMS;

EID: 77953027359     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0024-7     Document Type: Article

References (16)

1. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2008;93:3703-3716.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
3. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91:4612-4619.
4. Gentilella R, Bianchi C, Rossi A, Rotella CM. Exenatide: a review from pharmacology to clinical practice. Diabetes Obes Metab. 2009;11:544-556.
5. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14.
6. Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008;24:489- 496.
7. Norris SL, Lee N, Thakurta S, Chan BK. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26:837-846.
8. Lage MJ, Fabunmi R, Boye KS, Misurski DA. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. Adv Ther. 2009;26:217-229.
9. Lobo FS, Wagner S, Gross CR, Schommer JC. Addressing the issue of channeling bias in observational studies with propensity scores analysis. Res Social Adm Pharm. 2006;2:143-151.
10. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther. 2009;31:1116-1123.
11. American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care. 2008;31:596-615.
12. Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm. 2006;12:546-554.
13. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther. 2003;25:1017-1038.
14. Sullivan PW, Ghushchyan V, Ben-Joseph RH. The effect of obesity and cardiometabolic risk factors on expenditures and productivity in the United States. Obesity (Silver Spring). 2008;16:2155-2162.
15. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care. 2002;25:482-486.
16. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the 8 years following diagnosis. Diabetes Care. 1999;22:1116-1124.